Literature DB >> 19542666

Time trial: a prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers.

Vedang Murthy1, Tejpal Gupta, Avinash Kadam, Sarbani Ghosh-Laskar, Ashwini Budrukkar, Reenadevi Phurailatpam, Rajeshri Pai, Jaiprakash Agarwal.   

Abstract

INTRODUCTION: An ongoing institutional randomized clinical trial comparing three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) provided us an opportunity to document and compare the time-manpower burden with these high-precision techniques in head and neck cancers.
MATERIALS AND METHODS: A cohort of 20 consecutive patients in the ongoing trial was studied. The radiotherapy planning and delivery process was divided into well-defined steps and allocated human resource based on prevalent departmental practice. Person-hours for each step were calculated.
RESULTS: Twelve patients underwent IMRT and eight patients had 3D CRT. The prerandomization steps (upto and including approval of contours) were common between the two arms, and expectedly, the time taken to complete each step was similar. The planning step was carried out postrandomization and the median times were similar for 3D CRT (312 min, 5.2 person-hours) and IMRT (325.6 min, 5.4 person-hours). The median treatment delivery time taken per fraction varied between the two arms, with 3D CRT taking 15.2 min (0.6 person-hours), while IMRT taking 27.8 min (0.9 person-hours) (P< 0.001). The total treatment time was also significantly longer in the IMRT arm (median 27.7 versus 17.8 person-hours, P< 0.001). The entire process of IMRT took 48.5 person-hours while 3D CRT took a median of 37.3 person-hours. The monitor units delivered per fraction and the actual "beam-on" time was also statistically longer with IMRT.
CONCLUSIONS: IMRT required more person-hours than 3D CRT, the main difference being in the time taken to deliver the step-and-shoot IMRT and the patient-specific quality assurance associated with IMRT.

Entities:  

Mesh:

Year:  2009        PMID: 19542666     DOI: 10.4103/0973-1482.52800

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity-modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas.

Authors:  S Chatterjee; N Willis; S M Locks; J H Mott; C G Kelly
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  The potential of helical tomotherapy in the treatment of head and neck cancer.

Authors:  Dirk Van Gestel; Dirk Verellen; Lien Van De Voorde; Bie de Ost; Geert De Kerf; Olivier Vanderveken; Carl Van Laer; Danielle Van den Weyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Oncologist       Date:  2013-05-30

3.  IMRT and IGRT in head and neck cancer: Have we delivered what we promised?

Authors:  Gupta Tejpal; Agarwal Jaiprakash; Bannerjee Susovan; Sarbani Ghosh-Laskar; Vedang Murthy; Ashwini Budrukkar
Journal:  Indian J Surg Oncol       Date:  2010-11-21

4.  Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.

Authors:  Tejpal Gupta; Chandni Hotwani; Sadhana Kannan; Zubin Master; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar; Sarbani Ghosh-Laskar; Jai Prakash Agarwal
Journal:  Radiat Oncol       Date:  2015-03-15       Impact factor: 3.481

5.  RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.

Authors:  Dirk Van Gestel; Corine van Vliet-Vroegindeweij; Frank Van den Heuvel; Wouter Crijns; Ann Coelmont; Bie De Ost; Andrea Holt; Emmy Lamers; Yasmyne Geussens; Sandra Nuyts; Danielle Van den Weyngaert; Tim Van den Wyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Radiat Oncol       Date:  2013-02-20       Impact factor: 3.481

Review 6.  Clinical utility of RapidArc™ radiotherapy technology.

Authors:  Erminia Infusino
Journal:  Cancer Manag Res       Date:  2015-11-12       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.